WHO ICTRP trial
Mifepristone in various doses for treatment of uterine fibroid
CTRI/2025/07/091530 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2025/07/091530 |
|---|---|
| Public title | Mifepristone in various doses for treatment of uterine fibroid |
| Scientific title | Evaluation of efficacy and safety of mifepristone in different doses in management of patients with uterine leiomyoma- a prospective observational study - NIL |
| Primary sponsor | Jyotsna Puri |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 4 |
| Countries | India |
| Conditions | Health Condition 1: D259- Leiomyoma of uterus, unspecified |
| Interventions | Intervention1: Tab Mifepristone: 10 mg tablet will be given once daily for period of three months Intervention2: Tablet Mifepristone: Dose of 25 mg to be given once daily for three months (based on clinical decision). |
| Registration date | Jul 23, 2025 |
| Target size | 70 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: